The Oncology Institute Announces Certification to Administer Pluvicto Therapy in California
Introduction of Pluvicto Therapy: The Oncology Institute, Inc. has received certification to administer Pluvicto therapy for metastatic prostate cancer in their outpatient radiation oncology practices in California, moving away from hospital-only settings.
Impact on Patient Care: This new treatment option aims to enhance patient care by reducing hospitalization needs, aligning with TOI's mission to provide advanced, community-based cancer care while benefiting patients and payors.
Trade with 70% Backtested Accuracy
Analyst Views on TOI
About TOI
About the author
M33 Growth Partners with US Neurology Associates to Transform Neurology Care
- Strategic Partnership: M33 Growth partners with US Neurology Associates to enhance the quality of neurology care by integrating resources and infrastructure to meet the growing patient demand.
- Leadership Team: Nitin Jain as CEO and Brad Hively as Chairman bring extensive management experience in healthcare, which will drive the company's growth.
- Innovative Care Platform: USNA will deliver comprehensive care including in-office infusions, diagnostics, and clinical trials, aiming to improve patient experience and reduce care costs through a one-stop service.
- Value-Oriented Approach: USNA is committed to collaborating with payers to promote value-based care models, aiming to provide efficient and cost-effective neurology solutions through integrated community clinics.
The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care
- Leadership Changes: The Oncology Institute has appointed Rakesh Panda as Chief Information Officer, leveraging over 25 years of IT and digital transformation experience to advance the company's technology strategy, particularly in AI and data privacy, aimed at enhancing value-based cancer care.
- HR Strengthening: Nolan Mariano has been appointed Chief People Officer, overseeing HR operations and talent acquisition, and with 18 years of industry experience, he will enhance company culture and employee development to support the rapid growth of The Oncology Institute.
- Technology-Driven Care Platform: The new CIO will focus on the technology-enabled care delivery platform, driving innovations to improve patient experience and care quality, thereby strengthening the company's competitive position in the cancer care market.
- Sustained Growth Strategy: CEO Daniel Virnich emphasized the promotion of internal leaders, indicating the company's commitment to providing world-class community-based cancer care while continuing to experience rapid growth, further solidifying its leadership position in the industry.
Biotech Sector Sustains After-Hours Trading Gains
Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.
Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.
Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.
Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.
Needham Begins Coverage of Oncology Institute with Buy Rating and Sets Price Target at $5
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Major Stocks Including Elastic, Veeva Systems, and HIVE Digital Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 200 points on Friday.
Elastic NV Earnings Report: Elastic NV's shares dropped 12.3% in pre-market trading despite reporting adjusted earnings of 64 cents per share, surpassing analyst expectations, and quarterly revenue of $423.48 million, which also exceeded estimates.
Other Stocks Declining: Several other stocks experienced declines in pre-market trading, including Luda Technology Group Ltd (-11.1%), AnaptysBio Inc (-9.7%), and Sigma Lithium Corp (-8.4%).
Veeva Systems Performance: Veeva Systems Inc saw a 6.7% drop in pre-market trading despite posting strong third-quarter results and raising its fiscal year earnings and revenue estimates above analyst predictions.
TOI Reports Impressive Q3 2025 Performance, Increases Annual Forecast
Strong Q3 Performance: The Oncology Institute Inc. reported Q3 2025 revenue of $136.6 million, a 36.7% increase year-over-year, while narrowing its adjusted EBITDA loss to $3.5 million.
Net Loss and Guidance Update: The company experienced a net loss of $16.5 million in Q3 2025 and raised its full-year revenue guidance to $495 million to $505 million, up from $460 million to $480 million.
Leadership Changes: Kristin England has been appointed as Chief Administrative Officer to enhance business operations and technology strategy, including AI enablement.
Stock Performance: TOI's stock is currently trading at $3.41, reflecting an 11% increase in premarket trading, with a yearly trading range between $0.125 and $4.88.
M33 Growth Partners with US Neurology Associates to Transform Neurology Care
- Strategic Partnership: M33 Growth partners with US Neurology Associates to enhance the quality of neurology care by integrating resources and infrastructure to meet the growing patient demand.
- Leadership Team: Nitin Jain as CEO and Brad Hively as Chairman bring extensive management experience in healthcare, which will drive the company's growth.
- Innovative Care Platform: USNA will deliver comprehensive care including in-office infusions, diagnostics, and clinical trials, aiming to improve patient experience and reduce care costs through a one-stop service.
- Value-Oriented Approach: USNA is committed to collaborating with payers to promote value-based care models, aiming to provide efficient and cost-effective neurology solutions through integrated community clinics.
The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care
- Leadership Changes: The Oncology Institute has appointed Rakesh Panda as Chief Information Officer, leveraging over 25 years of IT and digital transformation experience to advance the company's technology strategy, particularly in AI and data privacy, aimed at enhancing value-based cancer care.
- HR Strengthening: Nolan Mariano has been appointed Chief People Officer, overseeing HR operations and talent acquisition, and with 18 years of industry experience, he will enhance company culture and employee development to support the rapid growth of The Oncology Institute.
- Technology-Driven Care Platform: The new CIO will focus on the technology-enabled care delivery platform, driving innovations to improve patient experience and care quality, thereby strengthening the company's competitive position in the cancer care market.
- Sustained Growth Strategy: CEO Daniel Virnich emphasized the promotion of internal leaders, indicating the company's commitment to providing world-class community-based cancer care while continuing to experience rapid growth, further solidifying its leadership position in the industry.
Biotech Sector Sustains After-Hours Trading Gains
Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.
Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.
Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.
Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.
Needham Begins Coverage of Oncology Institute with Buy Rating and Sets Price Target at $5
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Major Stocks Including Elastic, Veeva Systems, and HIVE Digital Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 200 points on Friday.
Elastic NV Earnings Report: Elastic NV's shares dropped 12.3% in pre-market trading despite reporting adjusted earnings of 64 cents per share, surpassing analyst expectations, and quarterly revenue of $423.48 million, which also exceeded estimates.
Other Stocks Declining: Several other stocks experienced declines in pre-market trading, including Luda Technology Group Ltd (-11.1%), AnaptysBio Inc (-9.7%), and Sigma Lithium Corp (-8.4%).
Veeva Systems Performance: Veeva Systems Inc saw a 6.7% drop in pre-market trading despite posting strong third-quarter results and raising its fiscal year earnings and revenue estimates above analyst predictions.
TOI Reports Impressive Q3 2025 Performance, Increases Annual Forecast
Strong Q3 Performance: The Oncology Institute Inc. reported Q3 2025 revenue of $136.6 million, a 36.7% increase year-over-year, while narrowing its adjusted EBITDA loss to $3.5 million.
Net Loss and Guidance Update: The company experienced a net loss of $16.5 million in Q3 2025 and raised its full-year revenue guidance to $495 million to $505 million, up from $460 million to $480 million.
Leadership Changes: Kristin England has been appointed as Chief Administrative Officer to enhance business operations and technology strategy, including AI enablement.
Stock Performance: TOI's stock is currently trading at $3.41, reflecting an 11% increase in premarket trading, with a yearly trading range between $0.125 and $4.88.
